Gansauge F, Link K H, Rilinger N, Kunz R, Beger H G
Chirurgische Klinik I, Universität Ulm.
Med Klin (Munich). 1995 Sep 15;90(9):501-5.
Even after resection median survival times in advanced pancreatic carcinoma are seldom more than one year. The aim of our study was to evaluate the effectivity of regional chemotherapy in patients suffering from unresectable pancreatic cancer.
From 2/92 until 11/94 32 patients with unresectable pancreatic cancer (17 patients stage III, 15 patients stage IV) were treated by celiac trunc infusion. One cycle consisted of mitoxantrone (d 1), 5-FU, folinic acid (d 2 to 4) and cisplatinum (d 5).
Besides a few severe complications, therapy was well tolerated in 101 cycles. In unresected patients with stage III tumors the median survival is 12 months compared to 4.8 months in patients with biliodigestive bypasses (p < 0.006) and 4 months in regionally infused patients stage IV compared to 2.7 months in untreated patients (n.s.).
Regional chemotherapy in advanced pancreatic carcinoma is well tolerated and increases median survival in patients with stage III tumors.
即使在切除术后，晚期胰腺癌的中位生存时间也很少超过一年。我们研究的目的是评估区域化疗对不可切除胰腺癌患者的有效性。
从1992年2月至1994年11月，对32例不可切除胰腺癌患者（17例Ⅲ期，15例Ⅳ期）进行腹腔干灌注治疗。一个周期包括米托蒽醌（第1天）、5-氟尿嘧啶、亚叶酸（第2至4天）和顺铂（第5天）。
除少数严重并发症外，101个周期的治疗耐受性良好。在未切除的Ⅲ期肿瘤患者中，中位生存期为12个月，而行胆肠吻合术的患者为4.8个月（p<0.006）；Ⅳ期区域灌注患者的中位生存期为4个月，未治疗患者为2.7个月（无统计学差异）。
晚期胰腺癌的区域化疗耐受性良好，可提高Ⅲ期肿瘤患者的中位生存期。
